Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.

Daryl Kai Ann Chia,Raghav Sundar,Guo Wei Kim,Jiajun Ang,Jeffrey Huey Yew Lum,Min En Nga,Chee Cheng Ean,Hon-Lyn Tan,Jingshan Ho,Natalie Ngoi,Matilda Lee,Vaishnavi Muthu,Gloria Chan,Angela Pang,Yvonne Ang,Joan Choo,Joline Si Jing Lim,Asim Shabbir,Wei Peng Yong,Jimmy Bok Yan So

Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.

2021

165Background: The addition of intraperitoneal (IP) paclitaxel (PTX) to systemic chemotherapy comprising taxane/fluoropyrimidine doublet has shown promising results for patients with gastric cancer...

Keywords:

Taxane
Oxaliplatin
Internal medicine
Medicine
Paclitaxel
Oncology
systemic chemotherapy
Phases of clinical research
Cancer
Capecitabine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations